IL310330A - Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling - Google Patents
Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signalingInfo
- Publication number
- IL310330A IL310330A IL310330A IL31033024A IL310330A IL 310330 A IL310330 A IL 310330A IL 310330 A IL310330 A IL 310330A IL 31033024 A IL31033024 A IL 31033024A IL 310330 A IL310330 A IL 310330A
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- tetrazol
- phenyl
- piperazin
- isobutyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227555P | 2021-07-30 | 2021-07-30 | |
| US202163227552P | 2021-07-30 | 2021-07-30 | |
| PCT/EP2022/071231 WO2023006893A1 (en) | 2021-07-30 | 2022-07-28 | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310330A true IL310330A (en) | 2024-03-01 |
Family
ID=83149285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310330A IL310330A (en) | 2021-07-30 | 2022-07-28 | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
Country Status (16)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022318349B2 (en) * | 2021-07-30 | 2025-12-18 | Confo Therapeutics N.V. | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
| KR20250011177A (ko) | 2022-05-17 | 2025-01-21 | 일라이 릴리 앤드 캄파니 | At2r 길항제 및 그의 용도 |
| TW202440553A (zh) * | 2023-03-29 | 2024-10-16 | 大陸商武漢人福創新藥物研發中心有限公司 | 作為at2r拮抗劑的雜環化合物 |
| TW202502346A (zh) * | 2023-06-16 | 2025-01-16 | 大陸商武漢人福創新藥物研發中心有限公司 | 作為at2r拮抗劑的雜環化合物及其用途 |
| TW202515864A (zh) | 2023-10-10 | 2025-04-16 | 大陸商武漢人福創新藥物研發中心有限公司 | 一種at2r拮抗劑及其用途 |
| WO2025180473A1 (zh) * | 2024-02-29 | 2025-09-04 | 上海汇伦医药股份有限公司 | 含四唑类化合物、其药物组合物及其用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU183178B (en) * | 1979-07-13 | 1984-04-28 | Thomae Gmbh Dr K | Process for preparing new carboxylic acid derivatives |
| AU675660B2 (en) * | 1992-07-17 | 1997-02-13 | Merck & Co., Inc. | Substituted biphenylmethylimidazopyridines |
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| CA2180190A1 (en) * | 1995-07-10 | 1997-01-11 | Kazumi Ogata | Benzylpiperazine derivatives |
| JPH09208570A (ja) * | 1995-07-10 | 1997-08-12 | Senju Pharmaceut Co Ltd | ベンジルピペラジン誘導体 |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
| ES2125206B1 (es) | 1997-07-21 | 1999-11-16 | Esteve Labor Dr | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| ES2325140T3 (es) | 1998-04-20 | 2009-08-26 | ABBOTT GMBH & CO. KG | Amidas sustituidas con heterociclos como inhibidores de la calpaina. |
| ES2165274B1 (es) * | 1999-06-04 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| HK1078086A1 (en) | 2003-04-09 | 2006-03-03 | 日本烟草产业株式会社 | Heteroaromatic pentacyclic compound and medicinal use thereof |
| NZ555334A (en) | 2004-12-24 | 2010-05-28 | Spinifex Pharm Pty Ltd | Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist |
| CN102295636A (zh) | 2005-07-29 | 2011-12-28 | 弗·哈夫曼-拉罗切有限公司 | 吲哚-3-基-羰基-哌啶和哌嗪衍生物 |
| ES2583528T3 (es) | 2010-09-07 | 2016-09-21 | Astellas Pharma Inc. | Compuesto de pirazoloquinolina |
| JP2012171868A (ja) * | 2011-02-17 | 2012-09-10 | Tsutomu Takeuchi | N−ヘテロアリールピペラジン誘導体を有効成分とするbaffの結合阻害剤 |
| WO2014159234A1 (en) | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | Glycosidase inhibitors |
| NZ630908A (en) | 2013-07-08 | 2017-08-25 | Novartis Ag | Heterocyclic compounds and methods of their use |
| SG10201900631TA (en) * | 2014-08-01 | 2019-02-27 | Nuevolution As | Compounds active towards bromodomains |
| WO2016154075A1 (en) | 2015-03-20 | 2016-09-29 | Vertex Pharmaceuticals Incorporated | Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway |
| JP7086395B2 (ja) | 2016-03-04 | 2022-06-20 | ヴァンダービルト ユニバーシティー | 置換インドールMcl-1阻害剤 |
| BR112018077075A2 (pt) * | 2016-06-29 | 2019-04-30 | Universite De Montreal | heterociclos de biarilmetila |
| WO2018057588A1 (en) | 2016-09-21 | 2018-03-29 | Vertex Pharmaceuticals Incorporated | Furo[3,2-b]pyridine compounds useful as inhibitors of the par-2 signaling pathway |
| JP7438962B2 (ja) | 2018-03-23 | 2024-02-27 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | 受容体阻害剤、同阻害剤を含む医薬組成物及びその使用 |
| EP3886844A4 (en) | 2018-11-28 | 2022-08-24 | H. Lundbeck A/S | Methods of treating disease with magl inhibitors |
| AU2022318349B2 (en) * | 2021-07-30 | 2025-12-18 | Confo Therapeutics N.V. | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
-
2022
- 2022-07-28 AU AU2022318349A patent/AU2022318349B2/en active Active
- 2022-07-28 US US18/293,160 patent/US20240368133A1/en active Pending
- 2022-07-28 MX MX2024001155A patent/MX2024001155A/es unknown
- 2022-07-28 EP EP22761413.8A patent/EP4377307A1/en active Pending
- 2022-07-28 PE PE2024000173A patent/PE20241304A1/es unknown
- 2022-07-28 KR KR1020247006999A patent/KR20240063881A/ko active Pending
- 2022-07-28 WO PCT/EP2022/071231 patent/WO2023006893A1/en not_active Ceased
- 2022-07-28 JP JP2024505546A patent/JP7637827B2/ja active Active
- 2022-07-28 IL IL310330A patent/IL310330A/en unknown
- 2022-07-28 CR CR20240041A patent/CR20240041A/es unknown
- 2022-07-28 CA CA3227194A patent/CA3227194A1/en active Pending
-
2024
- 2024-01-24 DO DO2024000017A patent/DOP2024000017A/es unknown
- 2024-01-25 CL CL2024000230A patent/CL2024000230A1/es unknown
- 2024-01-29 EC ECSENADI20247288A patent/ECSP24007288A/es unknown
- 2024-01-30 JO JOJO/P/2024/0019A patent/JOP20240019A1/ar unknown
- 2024-01-30 CO CONC2024/0000880A patent/CO2024000880A2/es unknown
-
2025
- 2025-02-17 JP JP2025023227A patent/JP7836437B2/ja active Active
- 2025-11-25 AU AU2025271263A patent/AU2025271263A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240063881A (ko) | 2024-05-13 |
| WO2023006893A1 (en) | 2023-02-02 |
| JP2025084799A (ja) | 2025-06-03 |
| CR20240041A (es) | 2024-06-04 |
| JP2024528127A (ja) | 2024-07-26 |
| MX2024001155A (es) | 2024-07-01 |
| EP4377307A1 (en) | 2024-06-05 |
| US20240368133A1 (en) | 2024-11-07 |
| CL2024000230A1 (es) | 2024-08-23 |
| CO2024000880A2 (es) | 2024-04-29 |
| JP7836437B2 (ja) | 2026-03-26 |
| JOP20240019A1 (ar) | 2024-01-30 |
| ECSP24007288A (es) | 2024-04-30 |
| CA3227194A1 (en) | 2023-02-02 |
| AU2022318349A1 (en) | 2024-02-15 |
| PE20241304A1 (es) | 2024-06-24 |
| DOP2024000017A (es) | 2024-06-16 |
| AU2022318349B2 (en) | 2025-12-18 |
| JP7637827B2 (ja) | 2025-02-28 |
| AU2025271263A1 (en) | 2025-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024502433A5 (cg-RX-API-DMAC7.html) | ||
| JP2022531801A5 (cg-RX-API-DMAC7.html) | ||
| DK2552920T3 (en) | UNKNOWN UNKNOWN NK-3 RECEPTOR SELECTIVE ANTAGONIST RELATIONS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTOR-MEDIUM DISORDERS | |
| RU2424242C2 (ru) | Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| JP2014521711A5 (cg-RX-API-DMAC7.html) | ||
| RU2010123874A (ru) | Пиридазиноновые производные в качестве ингибиторов parp | |
| JP2015522002A5 (cg-RX-API-DMAC7.html) | ||
| RU2007101544A (ru) | Антагонисты рецепторов высвобождающего гонадотропин гормона | |
| JP2013508404A5 (cg-RX-API-DMAC7.html) | ||
| IL187690A (en) | Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer | |
| JP2014511355A5 (cg-RX-API-DMAC7.html) | ||
| IL258577A (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| JP2020514267A5 (cg-RX-API-DMAC7.html) | ||
| JP2013526536A5 (cg-RX-API-DMAC7.html) | ||
| JP2012532931A5 (cg-RX-API-DMAC7.html) | ||
| AU2015242975A1 (en) | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | |
| RU2016124178A (ru) | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет | |
| RU2018123779A (ru) | Новые соединения | |
| JP2016519096A5 (cg-RX-API-DMAC7.html) | ||
| JP2014506929A5 (cg-RX-API-DMAC7.html) | ||
| WO2017212010A1 (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| RU2017134901A (ru) | Соединения 1-циано-пирролидинов в качестве ингибиторов USP30 | |
| JP2016525092A5 (cg-RX-API-DMAC7.html) | ||
| RU2013136778A (ru) | Ингибиторы гистондезацетилазы, композиции и способы их применения |